Close Menu

This article has been updated from a previous version to include comments made by Qiagen CEO Thierry Bernard in an earnings call Wednesday morning.

NEW YORK – Qiagen reported after the close of the market Tuesday fourth quarter revenue growth of 38 percent, driven by COVID-19-related sales, as the company beat Wall Street analyst estimates on the top and bottom line.

For the three months ended Dec. 31, 2020, Qiagen reported total revenues of $571.2 million compared to $413.5 million a year ago. On average, analysts had expected Q4 revenues of $548.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.